{
  "id": "5c896f60d558e5f232000003",
  "type": "factoid",
  "question": "What is the indication for KYMRIAH?",
  "ideal_answer": "Kymriah\u2122 has been approved for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B cell precursor acute lymphoblastic leukemia.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29501911"
  ],
  "snippets": [
    {
      "text": "Two autologous chimeric antigen receptor (CAR) T cell therapies (Kymriah\u2122 and Yescarta\u2122) were recently approved by the FDA. Kymriah\u2122 is for the treatment of pediatric patients and young adults with refractory or relapse (R/R) B cell precursor acute lymphoblastic leukemia and Yescarta\u2122 is for the treatment of adult patients with R/R large B cell lymphoma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29501911",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "children and young adults with refractory or relapse B cell precursor acute lymphoblastic leukemia"
}